Figure 2.

Bemarituzumab elicits potent induction of ADCC activity against FGFR2b-expressing cells. Specific lysis of target cells as a percentage of maximal lysis in the presence of varying concentrations of bemarituzumab or FPA144-F is shown: Ba/F3 cells expressing full-length human FGFR2b treated with bemarituzumab (Bema/FGFR2b); Ba/F3 cells expressing full-length human FGFR2b treated with FPA144-F (FPA144-F/GFGFR2b); Ba/F3 cells expressing full-length human FGFR2c treated with bemarituzumab (Bema/FGFR2c). Data are presented as mean ±standard error of mean (SEM); n = 3 per concentration/group